Global Mesenchymal Stem Cells Market by Source Of Isolation (Cord Blood, Bone Marrow) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global mesenchymal-stem cells market was valued at USD 2.5 billion in 2020. It is projected to grow at 12.6% compound annual growth rate (CAGR), between 2021 and 2028. The market is expected to grow due to an exponential increase in mesenchymal-stem cell (MSC) research and its implications for the field of regeneration medicine. Investments in the MSC market space are expected to be driven by the constantly changing landscape of stem cell therapies. Large-scale operational entities have begun to target small and emerging players with an operating strategy to acquire them in order to increase their market presence.

Market growth is expected to be accelerated by the strong pipeline of mesenchymal-derived products and emerging applications of mesenchymal cells. 10 products based on mesenchymal stem cell-derived products have been approved by regulatory agencies around the globe as of 2019. A large number of companies are also exploring the potential for MSCs to be used as therapeutics in the treatment of inflammatory diseases, which will boost the market growth.

Takeda/TiGenix's phase 3 clinical trial includes MSCs to treat complex perianal fistulas of Crohn's Disease. This clinical trial is currently the most successful in its late stage. These factors will likely increase the use of MSC products by key market entities and intensify the market competition. Recent COVID-19 pandemic has prompted industry and scientific participants to focus their attention on the development of MSC-based therapies. MSCs have the immunomodulating property that can prevent COVID-19-related respiratory infections.

More than 50 clinical trials involving MSCs have been reported as of July 2020. They are being used in the development therapeutics for SARS-CoV-2 infections. MSCs are also being used in increasing numbers of research projects related to the development of new vaccine platforms. In June 2020, for example, researchers in China presented a novel method of designing COVID-19 vaccinations that is based on engineered human MSCs. This approach has both promising and positive antibody responses.

Most mesenchymal stem cells are used in research and clinical settings. Commercial applications have comparatively less penetration. This can be attributed to the inability to standardize and regulate stem cell therapies, as well as ethical and safety concerns regarding human MSCs. To maintain market growth, it is imperative that regulations and standardization are improved in the mesenchymal-stem cell industry.

Insights on Products & Services

Products dominated the market, accounting for 79.1% of the total revenue in 2020. The cell and cell lines segment is a major contributor to this segment's revenues. Many market players are actively seeking to tap into this market space. They have undertaken various initiatives, including new product development and business expansion. These market players provide mesenchymal stem cell and cell lines for research.

Kits, media and reagents will experience the fastest growth rate at 13.4% between 2021-2028. The key factor driving the segment's rapid growth is the expansion of product lines by its competitors. Researchers from China created a fully chemically defined medium, NBVbe medium, in March 2020 that allows for the isolation of human MSCs. This product will aid in the optimization of MSC media, molecular characterization and clinical applications.

MSC workflows have made significant revenue gains through the continuous improvement of cryopreservation and mesenchymal stem cells culture. In 2020, the culture and cryopreservation workflows segment accounted for 44.8% of all revenue. This can be attributed to cell culture and cryopreservation techniques, which are essential to successful transitional research as well as basic research related to mesenchymal and stem cells.

Type Insights

Market leader, allogeneic mesenchymal stem cells (MSCs) accounted for 54.3% of the total revenue in 2020. Allogeneic mesenchymal and allogeneic MSCs have a high safety profile in clinical applications. The implantation of allogeneic MSCs will be a revolutionary cell-based therapeutic method due to their low immunogenicity and immunosuppressive qualities. This results in a decreased immune response which is a contributing factor to the success rate of allogeneic MSCs implantations.

However, autologous mesenchymal and stem cell technology has seen many advances over the years. This segment is forecast to grow at 13.2% per year. Many studies have been conducted with autologous MSCs to treat various diseases. In July 2019, Mayo Clinic researchers conducted a phase I/II research to examine intrathecal administration MSCs for the treatment of multiple system atrophy (MSA).

Source of Isolation Informations

Market leader, bone marrow, accounted for 25.8% of the total revenue in 2020. Mesenchymal stem cell isolation is made possible by bone marrow. These cells can differentiate into bone, cartilage, tendons and fibroblasts. They also have multilineage differentiation capabilities and can differentiate into fat, cardiac muscle cells and endothelial cell types. A December 2018 article stated that bone marrow aspirates taken from the pelvis are the most commonly used source for MSCs in clinical trials. This has led to the segment's dominance between 2021 and 2028.

However, MSCs derived primarily from adipose tissue have occupied the second spot in terms of revenue share. This segment is forecast to grow at 12.9% CAGR over the forecast period. These multipotent mesenchymal cells are capable of expressing multiple functions, including isolation, expansion, and growth, as well as robust cell concentration. These cells have unique properties that make them more attractive than other mesenchymal stem cell types. The use of autologous MSCs derived from adipose is also promising for organs that have been damaged or injured by disease or injury, and regenerative medicine.

Indication Insights

Mesenchymal Stem Cells market was dominated by the cardiovascular diseases segment, which accounted for 22.0% of the total revenue share in 2020. Pre-clinical research has shown that mesenchymal stem cell transplantation improves cardiovascular repair. This has increased the penetration of MSCs for cardiovascular disease indications. MSCs have properties that promote angiogenesis, increase apoptosis resistance and promote differentiation of myocardial cell lines.

A meta-analysis and systematic review published in May 2019 found that mesenchymal stem cells treatment is an effective treatment to treat heart failure. These factors will likely have a positive impact on segment growth over the next few years. The bone marrow-derived mesenchymal stem cells have been shown to undergo differentiation in vitro to form cartilage, fat linesages and bone.

This technology has been widely used in clinical applications related to Graft versus Host Disease, (GvHD), and contributed to the highest growth rate at 14.4% between 2021 and 2028. MSCs have been a key player in the development of cell therapies for oncology. 25 clinical trials that used MSCs to treat various cancer indications have been registered as of February 2020. From 2021 to 2028, the cancer indication segment will see a 13.1% CAGR.

Application Insights

In 2020, the disease modeling segment was the dominant market. It accounted for 35.8% of the total revenue. A cellular disease model with MSCs that are patient-specific is a great tool for pathological research. As a disease modeling tool, mesenchymal stem cell models derived from patient-induced pluripotent stem cells can be used. Research studies are increasingly using mesenchymal stem cells models to study the mechanisms behind chronic disorders. MSCs can also be used to assess non-hematological mesenchymal tumors like sarcomas. This has helped this segment gain prominence.

From 2021 to 2028, the cell engineering segment is expected to grow at 13.4%. The promising therapeutic approach to tissue engineering using mesenchymal stem cells has emerged. These cells are widely used due to their ability to expand, self-renew, and lower tumorigenic potential. In recent years, this market has seen a lot of demand for mesenchymal stem cells encapsulation techniques.

Regional Insights

North America was the dominant market, accounting for 52.1% of the total revenue in 2020. Numerous clinical trials are being conducted to determine if mesenchymal-derived stem cells are safe and effective as viable treatments for a variety of life-threatening diseases. The U.S. is home to many major companies involved in the commercialization and supply of MSCs. These factors have helped to make the region the dominant market.

The European countries will be able to adopt MSCs if they have a strong research base that can evaluate the potential effects of clinical-scale manufacturing of mesenchymal cells. This is in addition to better funding programs from different public and private agencies. This space will be dominated by countries in the Asia Pacific region.

Stem cell therapy has been growing in popularity due to limited financial support and access to healthcare in Asia Pacific. MSCs are accepted in this region due to their low operating costs and large population. China is also known as the global hub for gene and cell therapy development. It holds the second spot in terms of clinical trials, with over 1,000 clinical trials ongoing between 2017-2018.

Market Share Insights & Key Companies

To maintain their market position, market players are focusing on expanding their offerings by undertaking extensive R&D. They also seek to form alliances and partnerships that will help them. Due to the recent COVID-19 pandemic, many academic and research institutes have focused their efforts on developing a treatment regimen using mesenchymal-derived stem cells.

In April 2020, a group of US researchers was granted FDA approval to start a clinical trial to evaluate umbilical cord-derived stem cells for preventing lung inflammation in severe COVID-19 cases. Bayer AG, on the other hand invested USD 600 million in BlueRock Therapeutics in August 2019 to increase its market share in stem cell therapies. Market growth is expected to be supported by such notable acquisitions and mergers. The market leader in mesenchymal stem cell markets is:

• Thermo Fisher Scientific, Inc.

• Cell Applications, Inc.

• Axol Biosciences Ltd.

• Cytori Therapeutics Inc

• STEMCELL Technologies Inc

• Cyagen Biosciences Inc.

• Celprogen Inc

• BrainStorm Cell Therapeutics Inc.

• Stemedica Cell Technologies Inc

• Merck KGaA (MilliporeSigma).

• Smith+Nephew

• Lonza AG

• PromoCell GmbH

• ScienCell Research Laboratories

• American Type Culture Collection

Up Market Research published a new report titled “Mesenchymal Stem Cells Market research report which is segmented by Source Of Isolation (Cord Blood, Bone Marrow), By Players/Companies Cytori Therapeutics Inc, PromoCell GmbH, Celprogen Inc, American Type Culture Collection, Stemedica Cell Technologies Inc, Axol Biosciences Ltd, Lonza AG, Thermo Fisher Scientific Inc, Merck KGaA (MilliporeSigma), BrainStorm Cell Therapeutics Inc, Smith+Nephew, Cyagen Biosciences Inc, Cell Applications Inc, STEMCELL Technologies Inc, ScienCell Research Laboratories”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Mesenchymal Stem Cells Market Report Segments:

The market is segmented by Source Of Isolation (Cord Blood, Bone Marrow).

Mesenchymal Stem Cells Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Mesenchymal Stem Cells Market

Overview of the regional outlook of the Mesenchymal Stem Cells Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Mesenchymal Stem Cells Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Mesenchymal Stem Cells Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Cord Blood

                2. Bone Marrow

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Mesenchymal Stem Cells Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Mesenchymal Stem Cells Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.